ResultsIQ

ResultsIQ › Latest results › Molbio Diagnostics Limited

Molbio Diagnostics Limited Q2 FY27 results deck summary

NSE: MOLBIO · BSE: 544866

Results deck of 5 Nov 2026, summarised by AI from the filing.

Q2 FY27 total income fell to ₹264.8 cr on rate-contract negotiations, while management reiterated 25% topline growth guidance for FY27.

Key takeaways

  1. Q2 result Q2 FY27 total income was ₹264.8 cr (Q2 FY26: ₹581.4 cr), EBITDA ₹49.7 cr at 18.8% and PAT ₹7.7 cr at 2.9%.
  2. FY27 guidance Management reiterated guidance of 25% topline growth in FY27 over FY26.
  3. Q2 softness Q2 FY27 was softer as the company was in the midst of rate-contract negotiations, so the quarter does not reflect a full three months of sales.
  4. Exports Outside India rose to 21% of Q2 FY27 revenue from 7% in Q2 FY26 as the company expands its global footprint.
  5. Margin fall EBITDA margin fell to 18.8% in Q2 FY27 from 29.0% in Q2 FY26.

Original filing on BSE

Molbio Diagnostics Limited H1 FY27 results

As filed: Revenue ₹648 cr, EBITDA ₹150 cr, PAT ₹88.0 cr, EBITDA margin 23.2%.

Not scored. No result for the same half-year last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%. Not scored. No result for the same quarter last year. Share price after the results: +29.5% in 30 days (Nifty 500: −5.5%).

Past price moves after results do not indicate future moves. Not a recommendation.

Molbio Diagnostics Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.